Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles.

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, ...

"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD. In a recent interview with Urology Times ®, Joshua J. Meeks, MD, PhD, shared his thoughts on ...

Hear from 5 experts as they recap some of the top data from this year's AUA. Urology Times® was on-site at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada conducting ...

The phase 2 trial of (177Lu) rhPSMA-10.1 targets mCRPC, enrolling 82 patients across the US and the Netherlands. The study design aligns with the FDA's Project Olympus, focusing on higher radiation ...

Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB. In a study presented at the Society of Urodynamics, Female ...

“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP. Genetic testing can have a profound impact on prostate cancer treatment ...

Medicare payment reform is crucial due to declining reimbursement rates, threatening patient access and clinician well-being. HR 879 proposes eliminating cuts and adding inflation adjustments.

ImmunityBio received an FDA refusal to file letter for NAI in BCG-unresponsive NMIBC with papillary indication, despite prior encouragement to submit. The refusal does not impact the previous approval ...

Panelist discusses how benign prostatic hyperplasia (BPH) and its treatments impact men’s sexual health, emphasizing the importance of balancing symptom relief with sexual function preservation, and ...